Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
14.56
-0.06 (-0.41%)
At close: Oct 12, 2026, 4:00 PM EDT
14.57
+0.01 (0.07%)
After-hours: Oct 12, 2026, 7:54 PM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $99.31M in the quarter ending June 30, 2026, with 65.65% growth. This brings the company's revenue in the last twelve months to $324.97M, up 34.55% year-over-year. In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth. That makes Iovance Biotherapeutics the 13,942nd largest company in the world by revenue and 2,568th in the United States.
Revenue (ttm)
$324.97M
Revenue Growth
+34.55%
P/S Ratio
20.30
Revenue / Employee
$333,302
Employees
975
Market Cap
6.60B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 263.50M | 99.43M | 60.60% |
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ionis Pharmaceuticals | 874.09M |
| Mirum Pharmaceuticals | 618.07M |
| Ligand Pharmaceuticals | 290.54M |
| Rhythm Pharmaceuticals | 239.92M |
| Praxis Precision Medicines | 7.46M |
| CG Oncology | 6.23M |
| ABIVAX Société Anonyme | 5.33M |
IOVA News
- 4 days ago - Iovance Biotherapeutics price target raised to $11 from $6 at Baird - TheFly
- 11 days ago - Iovance Biotherapeutics appoints Berkowitz as CMO - TheFly
- 11 days ago - Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 12 days ago - Iovance Biotherapeutics price target raised to $18 from $14 at Wells Fargo - TheFly
- 13 days ago - Iovance Biotherapeutics rises 27.8% - TheFly
- 13 days ago - Iovance Biotherapeutics price target raised to $20 from $9 at H.C. Wainwright - TheFly
- 13 days ago - Iovance Biotherapeutics rises 25.9% - TheFly
- 13 days ago - Iovance Biotherapeutics raises FY26 revenue view to $410M-$420M - TheFly